同源康医药-B：联交所就实施H股全流通授出上市批准

Group 1 - The company, Tongyuan Kang Pharmaceutical-B (02410), has applied to the Stock Exchange Listing Committee for approval to convert 4.608 million non-listed shares held by one shareholder into 4.608 million H shares for listing and trading [1] - The Stock Exchange granted the listing approval on February 11, 2026 [1]